安莉芳控股(01388.HK)第三季銷售跌12% 料年度虧損或持續
安莉芳控股(01388.HK)公布,根據公司現有資料及對集團截至9月30日止九個月未經審核綜合管理賬目之初步審閱,加上上述原因以及經考慮相關期間政府補助收入減少,預計於相關期間將錄得公司擁有人應佔淨虧損約2,400萬元。
集團指,受限於中國消費市場從疫情中復甦的進展,若果上述的情況持續將對第四季的財務表現報成不利影響,目前預計該等因素可能會導致截至12月31日止年度股東應佔虧損持續,相比截至去年同期股東應佔虧損為約2,750萬元。
集團於第三季度期間的整體銷售按年下跌約12%。於第三季期間,已營運21個月以上的店舖之銷售較去年同期錄得雙位數跌幅。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.